Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Ash Bullement"'
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-3 (2024)
Externí odkaz:
https://doaj.org/article/7c32272ba0b847d2aa48e2afdae3e269
Autor:
Ash Bullement, Anna Willis, Amerah Amin, Michael Schlichting, Anthony James Hatswell, Murtuza Bharmal
Publikováno v:
BMC Medical Research Methodology, Vol 20, Iss 1, Pp 1-14 (2020)
Abstract Background Due to limited duration of follow up in clinical trials of cancer treatments, estimates of lifetime survival benefits are typically derived using statistical extrapolation methods. To justify the method used, a range of approaches
Externí odkaz:
https://doaj.org/article/4e9abc38fb674a40b18e974b71779478
Autor:
Sarah Gooding, I-Jun Lau, Mimi Sheikh, Pamela Roberts, Julia Wong, Emmy Dickens, Ash Bullement, Jamie Elvidge, Dawn Lee, Karthik Ramasamy
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0136207 (2015)
Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or refractory to bortezomib and lenalidomide, carries a poor prognosis. The healthcare costs of DRMM have not previously been reported. We analyzed detailed medical re
Externí odkaz:
https://doaj.org/article/864a5e8e6c3b4eb183398d331746fc22
Publikováno v:
Applied Health Economics and Health Policy. 21:385-394
Autor:
Jameel Nazir, Ash Bullement, Emma S Knowles, Gil Reynolds Diogo, Daniel Eriksson, Merel Langenfeld
Publikováno v:
Open Access Rheumatology : Research and Reviews
Open Access Rheumatology: Research and Reviews, Vol Volume 13, Pp 257-266 (2021)
Open Access Rheumatology: Research and Reviews, Vol Volume 13, Pp 257-266 (2021)
Ash Bullement,1 Emma S Knowles,1 Merel Langenfeld,2 Gil Reynolds Diogo,3 Jameel Nazir,4 Daniel Eriksson4 1Delta Hat, Nottingham, UK; 2Sobi, Woluwe-Saint-Lambert, Belgium; 3Sobi, Cambridge, UK; 4Sobi, Stockholm, SwedenCorrespondence: Daniel Eriksson E
Publikováno v:
PharmacoEconomics Open
Background\ud \ud A range of treatments for patients with severe hemophilia A (HA) have been developed over the last decade, allowing for reduced frequency of administration and improved outcomes (joint health and breakthrough bleeding rates). While
Publikováno v:
Bullement, A, Stevenson, M D, Baio, G, Shields, G E & Latimer, N R 2023, ' A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology Assessment ', Medical decision making, vol. 43, no. 5, pp. 610-620 . https://doi.org/10.1177/0272989X231168618
Background External evidence is commonly used to inform survival modeling for health technology assessment (HTA). While there are a range of methodological approaches that have been proposed, it is unclear which methods could be used and how they com
Publikováno v:
Applied Health Economics and Health Policy
Background\ud \ud Health state utility values (‘utilities’) are an integral part of health technology assessment. Though traditionally categorised by disease status in oncology (i.e. progression), several recent assessments have adopted values ca
Autor:
Sophie Robinson, G. J. Melendez-Torres, Louise Crathorne, Ash Bullement, Caroline Farmer, Elham Nikram, David Packman, Linda Long, Anthony J. Hatswell
Publikováno v:
PharmacoEconomics. 38:1309-1318
The UK National Institute for Health and Care Excellence (NICE) considered evidence for voretigene neparvovec (VN; Luxturna®) for the treatment of RPE65-mediated inherited retinal dystrophies (IRD) within its highly specialised technology programme.
Autor:
Anthony J. Hatswell, Tanja Podkonjak, Mark J Robinson, Gemma E Shields, Ross Selby, Ash Bullement, Eugene Benson
Publikováno v:
Bullement, A, Podkonjak, T, Robinson, M, Benson, E, Selby, R, Hatswell, A & Shields, G 2020, ' Real-world evidence use in assessments of cancer drugs by NICE ', International Journal of Technology Assessment in Health Care . https://doi.org/10.1017/S0266462320000434
ObjectiveTo establish how real-world evidence (RWE) has been used to inform single technology appraisals (STAs) of cancer drugs conducted by the National Institute for Health and Care Excellence (NICE).MethodsSTAs published by NICE from April 2011 to